Results 241 to 250 of about 216,413 (307)

Discontinuation of SGLT2i After a Urogenital Infection: A Population‐Based Matched Cohort Study of Patients With Type 2 Diabetes

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Sodium‐glucose cotransporter 2 inhibitors (SGLT2is) improve glycaemic control and cardiorenal outcomes in Type 2 diabetes, particularly in patients at elevated cardiovascular and kidney risk, yet discontinuation following infections appears common.
Christine Ljungberg, Mette Nørgaard, Christina Vandenbroucke‐Grauls, Michael Dalager‐Pedersen, Henrik Toft Sørensen, Reimar Wernich Thomsen   +5 more
wiley   +1 more source

Impact of Statin Use on Immunotherapy Outcomes and Efficacy in Non-Small Cell Lung Cancer Patients. [PDF]

Int J Mol Sci
Yakobson A, Agbarya A, Dudnik Y, Gothelf I, Miari A, Brenner R, Abu Jama A, Abu Yasin N, Dabah AEN, Meirovitz A, Maimon Rabinovich N, Shalata W.   +11 more
europepmc   +1 more source

Associations of Semaglutide With Skeletal Outcomes in People With Obesity, With and Without Type 2 Diabetes: A Target Trial Emulation

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To evaluate the associations between semaglutide initiation and long‐term skeletal outcomes in people with obesity, stratified by type 2 diabetes (T2D) status, using target trial emulation. Materials and Methods This retrospective cohort study used the TriNetX federated electronic health record network.
Yu‐Nan Huang, Min‐Yu Tsou, Pin‐Hung Li, Jo‐Ching Chen, Shao‐Chia Chen, Hao‐I Hsieh, Gideon Meyerowitz‐Katz, Yen‐Liang Liu, Pen‐Hua Su   +8 more
wiley   +1 more source

The lipid lowering efficacy of PCSK9 inhibitors alone vs. statins alone: a meta-analysis. [PDF]

Front Cardiovasc Med
Kyan K, Gornbein J, Saver J.
europepmc   +1 more source

Effects of Dapagliflozin on Cardiovascular Outcomes in Patients With Type 2 Diabetes at Risk of Liver Fibrosis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The fibrosis‐4 (FIB‐4) score is used to identify risk of advanced liver fibrosis. This post hoc analysis investigated its prognostic value for cardiovascular (CV) outcomes and its relevance to the effects of dapagliflozin. Materials and Methods DECLARE‐TIMI 58 was a randomised, placebo‐controlled phase 3 trial investigating dapagliflozin ...
Jan Oscarsson, Monika Huhn, Yunyun Jiang, Ingrid Gause‐Nilsson, Stephen D. Wiviott, Filipe A. Moura, John P. H. Wilding, Simona Cernea, Luc Van Gaal, Avivit Cahn, Deepak L. Bhatt, Peter A. Johansson, C. David Sjöström   +12 more
wiley   +1 more source

Estimated Oral Semaglutide Exposure Has Distinct Relationships With Glycaemic Response, Weight Loss and Gastrointestinal Tolerability

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Oral semaglutide absorption is subject to inter‐individual variability. We investigated whether estimated individual exposure (eCavg) provides predictive information beyond the prescribed dose in a real‐world cohort of patients with type 2 diabetes (T2D).
Gian Paolo Fadini, Mario Luca Morieri, Carlotta Boscaro, Benedetta Maria Bonora, Andrea Cignarella   +4 more
wiley   +1 more source

Lipid management in type 2 diabetes and non-HDL-cholesterol: target all atherogenic lipoproteins. [PDF]

Cardiovasc Diabetol
Brandts J, Verket M, Zambon A, Marx N, Müller-Wieland D, Federici M.   +5 more
europepmc   +1 more source

GLP‐1 Receptor Agonist Therapy and Cardiorenal Outcomes in Type 1 Diabetes: A Propensity‐Matched Real‐World Analysis

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Evidence on cardiovascular/renal outcomes associated with GLP‐1‐based therapies in type 1 diabetes (T1D) is limited. We examined the effects of GLP‐1‐based therapy on major clinical outcomes and safety, including diabetic ketoacidosis (DKA) and hypoglycemia risk, in adults with T1D in a large real‐world cohort.
Anastasios Tentolouris, Charalampos Filippatos, Nikolaos‐Iason Tepetes, Maria Gavriatopoulou, Evangelos Terpos, Alexandros Briasoulis, Kimon Stamatelopoulos, Theodosios Filippatos   +7 more
wiley   +1 more source